COMMUNIQUÉS West-GlobeNewswire

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation
27/03/2026
- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate [...]
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
27/03/2026
WALTHAM, Mass., March 27, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas,” “Zenas BioPharma” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the [...]
MEDVi Claims Evaluated: Most Affordable Tirzepatide GLP-1 Weight Loss Clinic Online — 2026 Search Trends and Publicly Available Pricing Information Context
27/03/2026
A 2026 informational overview of publicly available MEDVi tirzepatide GLP-1 pricing details, compounded medication access pathways, program structure, and regulatory context relevant to consumers researching affordable [...]
Gelatine Sculpt Claims Evaluated: Documenting the Gelatin Trick Recipe Investigation for Consumer Safety
27/03/2026
A 2026 consumer transparency report addressing Gelatine Sculpt's "bariatric jelly" terminology, gelatin trick recipe marketing references, GLP-1-related positioning, ingredient disclosure, proprietary blend context, and [...]
Radiant Health Centers Names Mark Gonzales Interim CEO Amid Period of Expansion
27/03/2026
Veteran Leader with 15+ Years of Service to Guide Growth, Increase Access to Care, and Deepen Community Impact Irvine, CA, March 26, 2026 (GLOBE NEWSWIRE) -- Radiant Health Centers today announced the appointment of [...]
Novo Nordisk A/S: Awiqli® approved in the US, the first and only once-weekly basal insulin treatment for adults with type 2 diabetes
27/03/2026
Awiqli ® (insulin icodec-abae) injection is the first-ever once-weekly basal insulin approved by the FDA Awiqli ® offers adults with type 2 diabetes an alternative to daily basal insulin injections, reducing these [...]
DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités
26/03/2026
Châtillon, France, 26 mars 2026 DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités Poursuite des avancées du programme de développement clinique du patch VIASKIN® Peanut [...]
DBV Technologies Reports Full Year 2025 Financial Results and Business Update
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Reports Full Year 2025 Financial Results and Business Update Continued advancing the VIASKIN® Peanut Patch clinical development programs in peanut-allergic toddlers (1 [...]
TOMI Environmental Solutions, Inc. to Hold Conference Call to Discuss Fourth Quarter 2025 Financial Results on March 31, 2026
26/03/2026
FREDERICK, Md., March 26, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc.® (“TOMI”) (NASDAQ: TOMZ), a global company specializing in disinfection and decontamination solutions, today announced it will report [...]
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
26/03/2026
- Announced up to $1.085 billion collaboration with Chugai Pharmaceutical Co. for multiple high-value therapeutics and completed $60.3 million oversubscribed private placement led by Samsara BioCapital with [...]
Spero Therapeutics Announces Fourth Quarter and Full Year 2025 Operating Results and Provides a Business Update
26/03/2026
Spero announced the resubmission of tebipenem HBr New Drug Application (NDA) to the FDA for complicated urinary tract infections (cUTI), including pyelonephritis in December 2025 In February, Spero’s licensing partner, [...]
IMDX Submits GraftAssureDx for FDA Review and Reports Q4 2025 Results
26/03/2026
Submitted GraftAssureDx™ for kidney transplant rejection testing for FDA review on Wednesday, March 25 Welcomed second favorable head-to-head data set from an independent study at large hospital comparing GraftAssure to [...]
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update
26/03/2026
Successfully completed Initial Public Offering (IPO) in February 2026, raising $172.5 million and listing on Nasdaq. Reported positive topline 12-month data from Phase 1/2 trial of the Bimatoprost Drug Pad-IOL System ( [...]
Iridex Reports Fourth Quarter and Full Year 2025 Financial Results
26/03/2026
Strong Q4 and Full Year 2025 Revenue Performance Underpinned by Continued Operational Efficiencies MOUNTAIN VIEW, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Iridex Corporation (Nasdaq: IRIX), a worldwide leader [...]
LeonaBio Reports Full Year 2025 Financial Results and Provides Business Update
26/03/2026
Acquired License to Phase 3 Lasofoxifene Development Program of Novel Selective Estrogen Receptor Modulator (SERM), a Potential Multi-Billion Dollar Opportunity as Treatment Option for Breast Cancer Patients with ESR1- [...]
Premier Health Announces Results of Shareholders’ Meeting
26/03/2026
MONTRÉAL, March 26, 2026 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “ Company ” or “ Premier Health ”), a leading Canadian Healthtech company, announces that all matters submitted to [...]
DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document
26/03/2026
Châtillon, France, March 26, 2026 DBV Technologies Announces Filing of 2025 Annual Report on Form 10-K and Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT [...]
DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025
26/03/2026
Châtillon, France, le 26 mars 2026 DBV Technologies publie son « Form 10-K » américain et son Document d’Enregistrement Universel 2025 DBV Technologies (Euronext : DBV – ISIN : FR0010417345 - Nasdaq : DBVT), une société [...]
XORTX Announces Results of Annual and Special Meeting of Shareholders
26/03/2026
CALGARY, Alberta, March 26, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on [...]

Pages